This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://fdazilla.com/483s/list/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n8https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
n21https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
n12https://www.fda.gov/
n18https://www.fda.gov/AboutFDA/CentersOffices/ORA/ORAElectronicReadingRoom/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15https://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Form_FDA_483
rdf:type
yago:Part113809207 yago:Word106286395 yago:Relation100031921 yago:Abstraction100002137 yago:WikicatUnitedStatesGovernmentForms yago:Form106290637 yago:LanguageUnit106284225
rdfs:label
Form FDA 483
rdfs:comment
The U.S. Food and Drug Administration (FDA) is authorized to perform inspections under the Federal Food, Drug, and Cosmetic Act, Sec. 704 (21 USC §374) "Factory Inspection". Form FDA 483, "Inspectional Observations," is a form used by the FDA to document and communicate concerns discovered during these inspections. Also referred to as "Form 483" or merely "483", it states thereon that it ... lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance
dcterms:subject
dbc:United_States_government_forms dbc:Food_and_Drug_Administration
dbo:wikiPageID
26833305
dbo:wikiPageRevisionID
1124398632
dbo:wikiPageWikiLink
dbr:Regulatory dbr:Food_and_Drug_Administration dbr:Timeline dbr:Header_(computing) dbr:CDER dbr:Dispute_resolution dbr:FDA_Warning_Letter dbr:Supply_chain dbr:Tissue_(biology) dbr:Human_cells dbr:Corrective_and_preventive_action dbr:21_CFR dbc:United_States_government_forms dbr:Bias dbr:Federal_Food,_Drug,_and_Cosmetic_Act dbr:United_States_Code dbc:Food_and_Drug_Administration dbr:Fiscal_year dbr:Freedom_of_Information_Act_(United_States) dbr:Sanitization_(classified_information) dbr:Business_process
dbo:wikiPageExternalLink
n11: n12: n15:default.htm n18:default.htm n21:UCM070279.pdf
owl:sameAs
wikidata:Q5469915 n8:4jh9H yago-res:Form_FDA_483 freebase:m.09v4ppy
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Lead_rewrite
dbo:abstract
The U.S. Food and Drug Administration (FDA) is authorized to perform inspections under the Federal Food, Drug, and Cosmetic Act, Sec. 704 (21 USC §374) "Factory Inspection". Form FDA 483, "Inspectional Observations," is a form used by the FDA to document and communicate concerns discovered during these inspections. Also referred to as "Form 483" or merely "483", it states thereon that it ... lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance A recipient of a 483 should respond to the FDA, addressing each item, indicating agreement and either providing a timeline for correction or requesting clarification of what the FDA requires. This response must be submitted within 15 business days regardless of the number of observations, as of September 2009. While a response is not compulsory, a good response can usually help a company avoid receiving a Warning Letter from the FDA, withholding of product approval, or plant shut-down. Most experts warn that responses should be comprehensive, well-reasoned, well-documented and timely, and that each observation should be addressed individually. The FDA encourages resolution of issues through informal mechanisms prior to the issuance of a 483. After issuance, manufacturers can use a formal two-tiered dispute resolution process described in the FDA document Guidance for Industry - Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP,and they have 30 calendar days to do so. The FDA refers to cellular and tissue-based products as "human cells, tissue (biology), and cellular or tissue-based products" (HCT/Ps). To protect the health of consumers, the agency also inspects these facilities and documents observations on a 483. The authority to do so is granted by 21 CFR 1271 Subpart F. The U.S. FDA has jurisdiction only within the United States. However, the supply chain for pharmaceuticals often extends far beyond the boundaries of the U.S., so the agency has an interest in assuring that foreign operations part of the U.S. supply chain are in an appropriate state of control, even though they have no legal authority to do so — although they can restrict importation into the U.S. The agency therefore performs foreign inspections, and observations for these are also captured on a 483. Regardless of the local language, the 483 will be written in English.
prov:wasDerivedFrom
wikipedia-en:Form_FDA_483?oldid=1124398632&ns=0
dbo:wikiPageLength
16634
foaf:isPrimaryTopicOf
wikipedia-en:Form_FDA_483